Panion expands the cooperation for the clinical development

With an agreement and contract that connects the well-reputed biostatistician Steve Radecki (USA)
to the coming clinical study in dogs with epilepsy, Panion's professional qualifications and competences are expanded. Clinical studies used for approval of medicines must be planned and evaluated with strict statistical methodology to ensure that the results are robust and significant. 

"We are very pleased with the cooperation with Steve Radecki, who has long experience in the field. This will ensure the validity of our studies and hence the usefulness in the future approval process", says Anja Holm, CEO of Panion Animal Health AB.

NEWS LETTER MARCH 13 2018

For further information, please contact:
Anja E. H. Holm, CEO | + 45-22 94 66 00  
anja.holm@panion-animalhealth.com 

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget. 

Nerladdningsbara filer

Panion in FDA pre-submission conference

Panion Animal Health AB develops a unique new gene therapy treatment for dogs with drug-resistant epilepsy and the primary targeted market is the USA. The company has just been assigned to a pre-submission conference for this product with staff and experts from the FDA's Center for Veterinary Medicine to take place in October in FDA-CVM's office, Maryland, USA. At the meeting, the product will be introduced, the development plan will be discussed, and comments from the experts will be sought for a faster and smoother access to approval and marketing.


Panion's emission is finalised and the dog safety study is progressing well

Panion's shares emission that was running from 16-30 May and raised appr. 5.2 MSEK before emission costs, has now been completed and all payments processed.





Nyemission registrerad hos Bolagsverket

Panion Animal Health AB:s (publ) nyemission är nu delregistrerad hos Bolagsverket


Panion's dog safety study experience a slight delay

Panion Animal Health AB develops a unique gene therapy treatment for dogs with idiopathic epilepsy. A safety study in dogs is currently running at the University of Copenhagen under the lead of Associate Professor David Woldbye, Department of Neuroscience, KU. Preliminary results from the study were expected in Q2, but due to circumstances outside Panion's influence, Panion has just been informed that this timing has been slightly delayed into Q3.


Panion presented at InvestorDagen in Århus, Denmark, the 12.th of June 2018

The progress and plans for Panion's development of the gene therapy treatment for dogs with epilepsy, and for Panion's business idea and vision, was presented by Anja Holm, CEO of Panion, at the InvestorDagen event in Århus, Denmark on the 12.th of June.


Panion in ITF-meeting at EMA


Panion presents for investors at InvestorDagen in Aarhus, DK on the 12.th of June 2018

Panion Animal Health AB is a Swedish registered company with shares on Spotlight/AktieTorget and with a unique product in development - a gene therapy treatment for epilepsy in dogs. We have  a strong Scandinavian cooperation in that half of Panion's management and board resides in Denmark. A safety study in dogs is currently running in Denmark in cooperation with the University of Copenhagen and under the lead of Associate professor David Woldbye, Department of neuroscience, KU.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: